Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

(2020) Philippe Gabriel Steg et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

(2020) Renato D. Lopes et al.   JAMA Cardiology

Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention

(2020) John H. Alexander et al.   CIRCULATION

Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy: Results from a Nationwide Danish Cohort Study

(2019) Nienke van Rein et al.   CIRCULATION

Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial

(2019) Jonas Oldgren et al.   EUROPEAN HEART JOURNAL

Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation

(2019) Manon C. Stam-Slob et al.   CIRCULATION

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI

(2019) Davide Capodanno et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

(2019) Juhani Knuuti et al.   EUROPEAN HEART JOURNAL

Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI

(2019) Stefan H. Hohnloser et al.   JACC-Cardiovascular Interventions

Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

(2019) Jurrien M. ten Berg et al.   AMERICAN JOURNAL OF CARDIOLOGY

Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials

(2019) Giuseppe Andò et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

(2018) Dominick J. Angiolillo et al.   CIRCULATION

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

(2017) Marco Valgimigli et al.   EUROPEAN HEART JOURNAL

Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction

(2017) Xiaoxi Yao et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

(2017) Francesco Costa et al.   LANCET

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

(2017) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

(2017) Charles V. Pollack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

(2017) Peter Brønnum Nielsen et al.   BMJ-British Medical Journal

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

(2017) Peter Brønnum Nielsen et al.   BMJ-British Medical Journal

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrilla

(2016) Christopher P. Cannon et al.   CLINICAL CARDIOLOGY

Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation

(2013) Ziad Hijazi et al.   CIRCULATION

Standardized Bleeding Definitions for Cardiovascular Clinical Trials

(2011) Roxana Mehran et al.   CIRCULATION

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE